• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球基金应如何利用资金效益信息来维持其对毕业国家的投资?

How Should Global Fund Use Value-for-Money Information to Sustain its Investments in Graduating Countries?

机构信息

Bureau of Health Administration, Ministry of Public Health, Nonthaburi, Thailand.

HITAP International Unit, Ministry of Public Health, Nonthaburi, Thailand.

出版信息

Int J Health Policy Manag. 2017 Sep 1;6(9):529-533. doi: 10.15171/ijhpm.2017.25.

DOI:10.15171/ijhpm.2017.25
PMID:28949465
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5582439/
Abstract

It has been debated whether the Global Fund (GF), which is supporting the implementation of programs on the prevention and control of HIV/AIDS, tuberculosis (TB) and malaria, should consider the value-for-money (VFM) for programs/interventions that they are supporting. In this paper, we critically analyze the uses of economic information for GF programs, not only to ensure accountability to their donors but also to support country governments in continuing investment in cost-effective interventions initiated by the GF despite the discontinuation of financial support after graduation. We demonstrate that VFM is not a static property of interventions and may depend on program start-up cost, economies of scales, the improvement of effectiveness and efficiency of providers once the program develops, and acceptance and adherence of the target population. Interventions that are cost-ineffective in the beginning may become cost-effective in later stages. We consider recent GF commitments towards value for money and recommend that the GF supports interventions with proven cost-effectiveness from program initiation as well as interventions that may be cost-effective afterwards. Thus, the GF and country governments should establish mechanisms to monitor cost-effectiveness of interventions invested over time.

摘要

全球基金(GF)一直在支持艾滋病、结核病(TB)和疟疾防治项目的实施,人们对其是否应考虑所支持项目/干预措施的成本效益(VFM)存在争议。本文批判性地分析了经济信息在 GF 项目中的使用,不仅是为了确保对捐助者负责,也是为了支持国家政府在 GF 毕业后停止财政支持后,继续对由 GF 启动的具有成本效益的干预措施进行投资。我们证明了 VFM 不是干预措施的静态属性,它可能取决于项目启动成本、规模经济、一旦项目发展提供方的效果和效率的提高,以及目标人群的接受和坚持。在开始时不具有成本效益的干预措施可能在后期变得具有成本效益。我们考虑了 GF 最近对成本效益的承诺,并建议 GF 从项目启动开始就支持具有成本效益的干预措施,以及以后可能具有成本效益的干预措施。因此,GF 和国家政府应建立机制,以随时间监测投资干预措施的成本效益。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed00/5582439/6fe521373b1f/ijhpm-6-529-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed00/5582439/6fe521373b1f/ijhpm-6-529-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed00/5582439/6fe521373b1f/ijhpm-6-529-g001.jpg

相似文献

1
How Should Global Fund Use Value-for-Money Information to Sustain its Investments in Graduating Countries?全球基金应如何利用资金效益信息来维持其对毕业国家的投资?
Int J Health Policy Manag. 2017 Sep 1;6(9):529-533. doi: 10.15171/ijhpm.2017.25.
2
[The Global Fund to fight HIV/AIDS, TB and Malaria 5-y: evaluation policy issues].[抗击艾滋病、结核病和疟疾全球基金5年:评估政策问题]
Bull Soc Pathol Exot. 2010 May;103(2):119-22. doi: 10.1007/s13149-010-0051-2. Epub 2010 Apr 7.
3
Thailand's HIV/AIDS program after weaning-off the global fund's support.在脱离全球基金支持后泰国的艾滋病毒/艾滋病项目。
BMC Public Health. 2013 Oct 25;13:1008. doi: 10.1186/1471-2458-13-1008.
4
[The Global Fund to fight HIV/AIDS, TB and malaria policy issues].[抗击艾滋病、结核病和疟疾全球基金政策问题]
Med Trop (Mars). 2010 Feb;70(1):19-27.
5
Tracking Global Fund HIV/AIDS resources used for sexual and reproductive health service integration: case study from Ethiopia.追踪全球基金用于性与生殖健康服务整合的艾滋病资源:来自埃塞俄比亚的案例研究。
Global Health. 2015 May 27;11:21. doi: 10.1186/s12992-015-0106-z.
6
Investing to end epidemics: the role of the Global Fund to control TB by 2030.投资终结流行病:全球基金到2030年控制结核病的作用。
Trans R Soc Trop Med Hyg. 2016 Mar;110(3):153-4. doi: 10.1093/trstmh/trw005.
7
Human rights and the Global Fund to Fight AIDS, Tuberculosis, and Malaria.人权与抗击艾滋病、结核病和疟疾全球基金
Health Hum Rights. 2014 Jun 14;16(1):134-47.
8
Critical interactions between Global Fund-supported programmes and health systems: a case study in Lao People's Democratic Republic.全球基金支持的项目与卫生系统之间的关键互动:老挝人民民主共和国的案例研究。
Health Policy Plan. 2010 Nov;25 Suppl 1:i37-42. doi: 10.1093/heapol/czq056.
9
Building to collective impact: the Global Fund support for measuring reduction in the burden of malaria.构建集体影响力:全球基金对衡量疟疾负担减轻情况的支持。
Am J Trop Med Hyg. 2007 Dec;77(6 Suppl):321-7.
10
Expanding the generation and use of economic and financial data to improve HIV program planning and efficiency: a global perspective.扩大经济和金融数据的生成和使用,以改善艾滋病毒规划和效率:全球视角。
J Acquir Immune Defic Syndr. 2011 Aug;57 Suppl 2:S104-8. doi: 10.1097/QAI.0b013e31821fa12d.

引用本文的文献

1
Evidence-Informed Deliberative Processes for HTA Around the Globe: Exploring the Next Frontiers of HTA and Best Practices Comment on "Use of Evidence-informed Deliberative Processes by Health Technology Assessment Agencies Around the Globe".全球范围内的卫生技术评估中的循证决策过程:探索卫生技术评估的下一个前沿和最佳实践 评“全球卫生技术评估机构使用循证决策过程”。
Int J Health Policy Manag. 2021 Mar 14;10(4):232-236. doi: 10.34172/ijhpm.2020.145.
2
Incorporating MCDA into HTA: challenges and potential solutions, with a focus on lower income settings.将多标准决策分析纳入卫生技术评估:挑战与潜在解决方案,重点关注低收入环境。
Cost Eff Resour Alloc. 2018 Nov 9;16(Suppl 1):43. doi: 10.1186/s12962-018-0125-8. eCollection 2018.
3

本文引用的文献

1
The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought.国际经济评估决策支持倡议参考案例:思想助力
Value Health. 2016 Dec;19(8):921-928. doi: 10.1016/j.jval.2016.04.015.
2
Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial.用于卫生政策评估的扩展成本效益分析:教程
Pharmacoeconomics. 2016 Sep;34(9):913-23. doi: 10.1007/s40273-016-0414-z.
3
The vulnerable aspects of application of "Health Technology Assessment".“卫生技术评估”应用中的薄弱环节。
A pragmatic approach to monitor and evaluate implementation and impact of differentiated ART delivery for global and national stakeholders.
一种实用的方法,用于监测和评估差异化 ART 提供方式在全球和国家利益相关者中的实施和影响。
J Int AIDS Soc. 2018 Mar;21(3). doi: 10.1002/jia2.25080.
4
Allocation rules for global donors.全球捐赠者的分配规则。
J Health Econ. 2018 Mar;58:67-75. doi: 10.1016/j.jhealeco.2018.02.003. Epub 2018 Feb 8.
5
We need a NICE for global development spending.我们需要一个用于全球发展支出的“国家健康与临床优化研究所”(NICE)。 注释:这里NICE一般指英国的国家健康与临床优化研究所(National Institute for Health and Care Excellence ) ,如果没有特殊语境,直接保留英文缩写更合适,但如果要求必须翻译出来,就是上述译文 。具体需结合上下文判断 。
F1000Res. 2017 Jul 25;6:1223. doi: 10.12688/f1000research.11863.1. eCollection 2017.
Int J Technol Assess Health Care. 2015 Jan;31(3):197-8. doi: 10.1017/S0266462315000288. Epub 2015 Jun 23.
4
Distributional Cost-Effectiveness Analysis: A Tutorial.分布性成本效益分析:教程
Med Decis Making. 2016 Jan;36(1):8-19. doi: 10.1177/0272989X15583266. Epub 2015 Apr 23.
5
The use of economic evaluation for guiding the pharmaceutical reimbursement list in Thailand.在泰国,运用经济评估来指导药品报销目录。
Z Evid Fortbild Qual Gesundhwes. 2014;108(7):397-404. doi: 10.1016/j.zefq.2014.06.017. Epub 2014 Aug 23.
6
Using health technology assessment for informing coverage decisions in Thailand.利用健康技术评估为泰国的覆盖决策提供信息。
J Comp Eff Res. 2012 Mar;1(2):137-46. doi: 10.2217/cer.12.10.
7
Health technology assessments as a mechanism for increased value for money: recommendations to the Global Fund.健康技术评估作为提高资金价值的机制:向全球基金提出的建议。
Global Health. 2013 Aug 21;9:35. doi: 10.1186/1744-8603-9-35.
8
Health technology assessment and its role in the future development of the Indian healthcare sector.卫生技术评估及其在印度医疗保健部门未来发展中的作用。
Perspect Clin Res. 2012 Apr;3(2):66-72. doi: 10.4103/2229-3485.96449.
9
Burden of disease in Thailand: changes in health gap between 1999 and 2004.泰国的疾病负担:1999 年至 2004 年间健康差距的变化。
BMC Public Health. 2011 Jan 26;11:53. doi: 10.1186/1471-2458-11-53.
10
Helping poorer countries make locally informed health decisions.帮助较贫穷国家做出基于当地情况的卫生决策。
BMJ. 2010 Jul 16;341:c3651. doi: 10.1136/bmj.c3651.